Single-centre experience of 85 patients with a continuous-flow left ventricular assist device: clinical practice and outcome after extended support

Sjoukje I. Lok*, Jerson R. Martina, Tim Hesselink, Ben F. M. Rodermans, Nelienke Hulstein, Bjorn Winkens, Corinne Klopping, J. Hans Kirkels, Pieter A. Doevendans, Faiz Ramjankhan, Roel A. de Weger, Nicolaas de Jonge, Jaap R. Lahpor

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Web of Science)


We evaluated our single-centre clinical experience with the HeartMate II (HM II) left ventricular assist device (LVAD) as a bridge to transplantation (BTT) in end-stage heart failure (HF) patients. Survival rates, echocardiographic parameters, laboratory values and adverse events of 85 consecutive patients supported with a HM II were evaluated. Overall, mean age was 45 +/- 13 years, 62 (73%) were male and non-ischaemic dilatated cardiomyopathy was present in 60 (71%) patients. The median duration of mechanical support was 387 days (IQR 150-600), with a range of 1-1835 days. The 6-month, 1-, 2-, 3- and 4-year survival rates during HM II LVAD support were 85, 81, 76, 76 and 68%, respectively. Echocardiographic parameters demonstrated effective left ventricular unloading, while laboratory results reflected adequate organ perfusion. However, HM II support was associated with adverse events, such as infections in 42 patients (49%; 0.67 events/patient-year), cardiac arrhythmia in 44 (52%; 0.86 events/patient-year), bleeding complications in 32 (38%; 0.43 events/patient-year) and neurological dysfunction in 17 (20%; 0.19 events/patient-year). In view of the increasing shortage of donor hearts, HM II LVAD support may be considered a life-saving treatment in end-stage HF patients, with good survival. However, it is still associated with some serious adverse events, of which neurological complications are the most critical.
Original languageEnglish
Pages (from-to)E233-E238
JournalEuropean Journal of Cardio-Thoracic Surgery
Issue number3
Publication statusPublished - Sept 2013


  • Continuous-flow LVAD
  • HeartMate II
  • Survival
  • Adverse events

Cite this